Compositions and methods of treating middle-of-the night insomnia

a technology of compositions and methods, applied in the direction of drug compositions, biocides, suppositories delivery, etc., can solve the problems of unsuitable hypnotic medications for treating motn insomnia, unnecessary medication and overmedication of persons

Inactive Publication Date: 2007-12-13
TRANSCEPT PHARMA
View PDF99 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0031] administering a solid pharmaceutical composition comprising zolpidem in an amount less than 5 mg and a binary buffer, to a subject who awakens from sleep and desires to resume sleep for less than 5 hours,
[0032] wherein the solid pharmaceutical composition provides del...

Problems solved by technology

Unfortunately, currently available hypnotic medications are unsuitable for treating MOTN insomnia because they are slow to induce sleep (e.g., zaleplon) and/or require administration prior to about 7 to 9 hours in bed to avoid residual sleepiness in the morning (e.g....

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions and methods of treating middle-of-the night insomnia
  • Compositions and methods of treating middle-of-the night insomnia
  • Compositions and methods of treating middle-of-the night insomnia

Examples

Experimental program
Comparison scheme
Effect test

example 1

Low Dose Zolpidem Lozenge Compositions

[0197] Individuals suffering from middle-of-the-night insomnia are given lozenges containing 0 mg, 1.0 mg, 1.75 mg, or 3.5 mg zolpidem for sublingual delivery that are prepared according to the formulations set forth in Table 3.

TABLE 3Low dose zolpidem lozenge formulations.Quantity (mg / lozenge)StrengthComponentPlacebo1.0 mg1.75 mg1.75 mg3.5 mgZolpidem hemitartrate01.01.751.753.5Pharmaburst ™ B214314269.75141.25139.5Consisting of:mannitolsorbitolcrospovidonesilicon dioxideCroscarmellose sodium101051010Sodium carbonate17178.51717Sodium bicarbonate232311.52323Natural and artificial6.56.53.256.56.5spearmint FONA#913.004Silicon dioxide5.55.52.755.55.5Sucralose1.51.50.751.51.5Magnesium stearate3.53.51.753.53.5Total lozenge weight210210105210210

[0198] The individuals self-administer one lozenge of the above formulations when their sleep is interrupted and they have at least 2 hours of sleep time remaining. Upon awakening, the individuals provide a s...

example 2

Pharmacokinetic and Pharmacodynamic Investigation of Low Dose Zolpidem Lozenge Compositions

[0200] This example provides an evaluation of the daytime dose-dependent pharmacokinetic and pharmacodynamic effects of the 1.0 mg, 1.75 mg, and 3.5 mg zolpidem lozenges described in Table 3 above.

Summary

[0201] Currently, no medications are available to be used on a pro re nata basis for patients who have middle-of-the-night (MOTN) awakening and who have difficulty falling back asleep. An appropriate therapeutic agent for such insomnia would enable patients to return to sleep rapidly and wake up in the morning without residual effects. This study illustrates, inter alia, that the low dose zolpidem lozenges of the present invention enhance rapid systemic delivery of zolpidem without affecting other pharmacokinetic parameters.

[0202] Healthy adults (n=24; mean age=37.6 yrs) participated in this double-blind, placebo-controlled, 4-way crossover study of 2 consecutive days of morning dosing wi...

example 3

Low Dose Zolpidem Tablet Composition

[0232] An immediate release peroral (PO) tablet containing a low dose of zolpidem can be prepared according to the formulation set forth in Table 5.

TABLE 5Low dose zolpidem tablet formulation.ComponentQuantity (mg)Zolpidem Hemitartrate3.5Povidone K29 / 3215.0Sodium Starch Glycolate (SSG)7.5Starch 150015.0Lactose Fast Flow82.0Prosolv SMCC 9065.5Sodium bicarbonate40Magnesium Stearate1.5Total230

Manufacturing Process

[0233] Dispensing: Screen the zolpidem hemitartrate and excipients through screen #30. Dispense the required quantities of each ingredient.

[0234] Blending: [0235] 1. Transfer the zolpidem hemitartrate and Povidone K 29 / 32 to a V-Shell blender and blend for 2 min. [0236] 2. Add SSG and Starch 1500 to Step 1 and blend for another 2 min. [0237] 3. Add Lactose Fast Flow and Prosolv SMCC 90 to Step 2 and blend for another 10 min. [0238] 4. Mix an equal amount of the blend from Step 3 with magnesium stearate or sodium stearyl fumarate and tr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Massaaaaaaaaaa
Massaaaaaaaaaa
Login to view more

Abstract

The present invention provides compositions and methods for treating middle-of-the-night insomnia without residual sedative effects upon awakening by administering low doses (about 5 mg or less) of zolpidem or a salt thereof.

Description

CROSS-REFERENCES TO RELATED APPLICATIONS [0001] This application is a continuation-in-part of PCT / US06 / 20502, filed May 23, 2006, and a continuation-in-part of each of Nonprovisional application Ser. No. 11 / 439,873, filed May 23, 2006, Nonprovisional application Ser. No. 11 / 440,410, filed May 23, 2006, Nonprovisional application Ser. No. 11 / 439,874, filed May 23, 2006 and Nonprovisional 11 / 439,884, filed May 23, 2006, and each of which claims the benefit of U.S. Provisional Application No. 60 / 684,842, filed May 25, 2005, U.S. Provisional Application No. 60 / 741,673, filed Dec. 1, 2005, U.S. Provisional Application No. 60 / 788,340, filed Mar. 31, 2006, and U.S. Provisional Application No. 60 / 788,249, filed Mar. 31, 2006, the disclosures of which are hereby incorporated by reference in their entirety for all purposes.BACKGROUND OF THE INVENTION [0002] Until recently, medical literature has recognized four types of insomnia, including sleep onset insomnia (e.g., trouble falling asleep at...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4178A61P43/00
CPCA61K9/0056A61K9/0058A61K9/006A61K9/02A61K9/2009A61K31/4745A61K9/2018A61K9/2027A61K9/2054A61K9/2059A61K31/437A61K9/2013A61P25/00A61P25/20A61P43/00
Inventor SINGH, NIKHILESH N.PATHER, SATHASIVAN I.
Owner TRANSCEPT PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap